Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: J Intern Med. 2017 May 31;282(1):76–93. doi: 10.1111/joim.12619

Figure 6. Beneficial effects of haptoglobin β subunit in experimental sepsis.

Figure 6

(A–C) Administration of haptoglobin β subunit confers protection against lethal sepsis in wild type (A) and haptoglobin−/− mice (C) partly through reducing systemic cytokine accumulation and increase IL-10 release (B).

(A) C57BL/6 mice (male, 8–10 weeks of age) were subjected to CLP surgery. Recombinant human haptoglobin (Hp) β was administered at 200 μg per mouse (in 200 μl PBS injected intraperitoneally) once a day for 3 days starting at 24 hours after CLP surgery. Mice in the control group received vehicle (PBS) only. Animal survival was monitored for two weeks (n = 22 per group). *: P < 0.05 vs. vehicle control group.

(B) Male wild type (C57BL/6) mice were subjected to CLP surgery and received haptoglobin β (200 μg/mouse) or vehicle (PBS) IP injection at 24 and 36 hours post-CLP surgery, and were euthanized at 48 hour post CLP. Serum levels of HMGB1, IL-6, TNF and IL-10 were measured (n = 8 or 10 mice per group). *: P <0.05 vs. CLP-vehicle group.

(C) Haptoglobin−/− mice (male, 8–12 weeks of age) were subjected to CLP. Mice received administration of recombinant haptoglobin β (or vehicle) daily for 3 days at 10 or 100 μg/mouse beginning at 24 hours after CLP surgery. Animal survival was monitored for 2 weeks (n = 22 mice per group). *: P<0.05 vs. vehicle control group.